Breaking Down Heilongjiang ZBD Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Heilongjiang ZBD Pharmaceutical Co., Ltd., founded in 1996, has grown into a major healthcare player in Heilongjiang with approximately 2,349 employees and a diverse portfolio of more than 200 products spanning cardiovascular, neurology and oncology, reporting revenue of ¥2.5 billion in 2022 (an 18% increase year‑on‑year) while biopharmaceuticals rose to 35% of sales in 2022 from 30% in 2021; the company's mission to enhance human health through innovation and affordable quality is reinforced by a customer retention rate above 85% over three years and a customer satisfaction score of 92% in 2023, its vision is backed by an R&D spend of about 15% of annual revenue and 30 patent applications filed in the last fiscal year, and its core values - quality, innovation, customer focus and sustainability - are reflected in operational gains including a 22% reduction in carbon emissions in 2022 versus 2020 and strategic initiatives for international expansion

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) - Intro

• Founded: 1996
• Listed: Shanghai Stock Exchange (603567.SS)
• Employees: ~2,349
• Core businesses: prescription pharmaceuticals, OTC medications, cultivation & processing of medicinal herbs, R&D and contract manufacturing

• End-to-end supply chain: seed-to-table control of medicinal herb inputs through GMP-certified production lines
• Quality & compliance: multi-tier QC, regulatory submissions for national approvals, and ISO/GMP alignment across facilities
• R&D orientation: formulation optimization, clinical study support, and integration of traditional Chinese medicine (TCM) with modern pharmacology

• Domestic market leadership in selected TCM and OTC categories, with growing hospital sales for certain prescription compounds
• Diversified revenue model combining finished products, API supply, and herbal raw-material sales
• International ambitions: export channels under development and selective partnerships for overseas registration and distribution

• Mission - Deliver safe, effective and accessible healthcare solutions by combining herbal tradition with scientific rigor.
• Vision - Become a globally respected integrated pharmaceutical enterprise that advances public health through innovation and sustainable cultivation of medicinal resources.
• Core values - Quality-first; Scientific integrity; Sustainable sourcing; Patient-centricity; Collaborative partnerships.

• Quality systems: batch traceability, stability testing, and third-party testing protocols to ensure regulatory compliance.
• Sustainable cultivation: standardized planting areas, reduced pesticide use, and water-management measures in herb production zones.
• Supply security: vertical integration reduces raw-material volatility and supports predictable COGS management.

• Allocate R&D resources toward formulation upgrades, bioactive component standardization, and registration dossiers for both domestic and target export markets.
• Pursue strategic alliances with research institutes, hospitals, and selected international distributors to accelerate product approvals and market entry.

• Revenue diversification and stable domestic demand support steady cash generation; reinvestment into R&D and compliance is prioritized.
• Key performance indicators tracked for investor relations: revenue growth, gross margin stability, new product approvals, and export contract wins.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) - Overview

Mission Statement

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) is committed to enhancing human health through innovative and high-quality pharmaceutical products. The company's mission emphasizes value-driven practices focused on innovation, sustainability, and competitive pricing, driving accessible healthcare solutions across core therapeutic areas.

• Deliver safe, effective medicines with a focus on patient outcomes.
• Invest in R&D to accelerate biopharmaceutical innovation.
• Maintain cost-competitive manufacturing and sustainable operations.
• Foster long-term customer relationships and market trust.

Vision

To be a leading integrated pharmaceutical company recognized for breakthrough biopharmaceuticals and a diverse, high-quality portfolio that improves global health standards.

• Expand global reach while maintaining strong domestic leadership.
• Transform a growing share of sales to biologics and advanced therapeutics.
• Scale production capacity and pipeline to support long-term growth.

Core Values

• Patient-first ethics and clinical integrity.
• Continuous innovation and scientific rigor.
• Accountability, transparency, and regulatory compliance.
• Sustainability in environmental and social governance.
• Customer focus reflected in measurable retention and satisfaction.

Key Strategic Metrics

Strategic focus areas include expanding R&D investment into biologics, diversifying the product mix across major therapeutic areas, and optimizing manufacturing scale to support cost leadership and sustainable growth. For investor-oriented context and stakeholder insights, see Exploring Heilongjiang ZBD Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) - Mission Statement

• Invest in R&D to discover and develop differentiated therapies.
• Deliver reliable, safe, and affordable pharmaceutical products to domestic and international markets.
• Create long-term value for patients, employees, shareholders, and partners.
• Adhere to environmental, social, and governance (ESG) responsibilities in manufacturing and distribution.

Vision Statement

• Global presence with an expanding export footprint across Asia, Europe, and emerging markets.
• Leadership in specialty generics and novel formulations backed by robust IP development.
• Customer-centric service models that drive loyalty and high satisfaction scores.

Core Values

• Innovation: Continuous investment in R&D (≈15% of revenue) and patentees to deliver differentiated therapies.
• Integrity: Compliance-driven operations, transparent reporting, and ethical conduct across the value chain.
• Quality: GMP-compliant manufacturing and rigorous quality control to ensure patient safety.
• Customer Focus: Maintain and improve a strong customer satisfaction score (92% in 2023).
• Collaboration: Strategic partnerships and licensing to accelerate global reach and product pipelines.

Heilongjiang ZBD Pharmaceutical Co., Ltd. (603567.SS) - Vision Statement

• Quality: rigorous GMP-compliant manufacturing, batch-release controls and post-market surveillance to ensure product safety and efficacy.
• Innovation: sustained investment in R&D to accelerate novel formulations, bioactive compound development and process improvements.
• Customer focus: prioritizing patient outcomes and client relationships; customer retention has remained consistently above 85% over the past three years (2021-2023).
• Sustainability: commitment to reducing environmental impact, with a reported 22% reduction in carbon emissions in 2022 versus 2020 baseline.

• Quality systems and certifications rolled out across manufacturing sites to reduce batch deviation rates and improve time-to-market for critical therapies.
• R&D pipeline prioritization to convert basic research into clinical-stage assets and differentiated generics.
• Customer service and distribution optimization to maintain high retention and broaden institutional contracts.
• Energy efficiency and emissions control projects to sustain reductions in greenhouse gases and resource consumption.